CanSinoBIO's 3rd vaccine plant starts full production to boost annual capacity
By

In-Depth reporter covering COVID-19 vaccines and health, Tibetan issue, China-ASEAN relations, among others.

Hu Yuwei
and Zhao Juecheng, Published: 2021/4/27 22:48:02
Photo: Hu Yuwei and Zhao Juecheng/GT
Editor's Note:
The Global Times recently visited Tianjin-based CanSinoBIO's third production plant as it rolled out the latest batch of COVID-19 vaccines. The 15,000-square-meter plant complies with the international Good Manufacture Practice of Medical Products (GMP) standards and has an automatic line for filling syringes and vials. The vaccine Ad5-nCoV is effective with a single dose and has already obtained approval for emergency use in Mexico, Pakistan and Hungary. With its third plant in full production, CanSinoBIO’s overall annual output capacity is expected to reach 300 million doses. The preliminary results of Phase III clinical trials show that its efficacy against symptomatic COVID-19 cases is 65.28 percent 28 days after vaccination, and 68.83 percent after 14 days. For severe cases, the vaccine reported 90.98 percent and 95.47 percent efficacy after 28 days and 14 days of single dose vaccination, respectively.(Photos: Hu Yuwei and Zhao Juecheng/GT)

Photo: Hu Yuwei and Zhao Juecheng/GT
Photo: Hu Yuwei and Zhao Juecheng/GT
Photo: Hu Yuwei and Zhao Juecheng/GT
Photo: Hu Yuwei and Zhao Juecheng/GT
Photo: Hu Yuwei and Zhao Juecheng/GT
Photo: Hu Yuwei and Zhao Juecheng/GT
blog comments powered by Disqus